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The Editorial on the Research Topic
Liver Myofibroblasts
Myofibroblasts (MFB) were first identified in the granulation tissue of healing wounds. They
have features of both fibroblasts and smooth muscle cells. In contrast to fibroblasts they contain
cytoplasmic actin microfilaments (stress fibers) connected to the extracellular matrix (ECM) by
focal contacts. MFB are connected to each other by adherens and gap junctions. Mechanical
forces produced by their contraction facilitate wound closure. Prominent stress fibers can be used
to identify MFB in the tissue. They are of mesenchymal origin and are produced by activation
and transdifferentiation of quiescent cell precursors after tissue injury. They are not found in
normal liver but they appear in large numbers in damaged liver and become a major source
of ECM proteins that replace functional tissue. MFB precursors in the liver are hepatic stellate
cells (HSC), portal fibroblasts, and circulating bone marrow-derived collagen-producing cells
(fibrocytes). They may also arise in a process termed epithelial-to-mesenchymal transition in
which epithelial cells acquire a mesenchymal phenotype. Based on the important role of MFB,
the knowledge of the transdifferentiation process is critical to understanding the development
liver fibrosis. Profibrogenic and proinflammatory cytokines produced by macrophages and T cells
regulate fibrogenesis. TGF-β1, the main profibrogenic cytokine, is also produced by MFB and
stimulates ECM production in an autocrine manner. Mechanical factors play a role in fibrosis
development. Tissue tension facilitates TGF-β1 production and α-smooth actin expression, which
in turn increases tension development. MFB are susceptible to apoptosis, their disappearance is
important for fibrosis reversibility, and they may be a target of anti-fibrogenic therapy.
With the important role of MFB in the development of liver fibrosis in mind, leading experts
in the field share their current perspectives on these cells in this Research Topic. As reviewed by
Lepreux and Desmouliere, MFB are found in fetal liver and they reappear during liver injury. They
are involved in tissue repair, in liver regeneration, and in liver cancer. HSC-derivedMFB are studied
in most cases. El Mourabit et al. have described a method to isolate MFB precursors from the rat
biliary tree. These cells are highly proliferative and can be easily multiplied in vitro. Portal MFB
differ in the expression of several genes from HSC-derived MFB, highlighting the distinct origin
of the respective cell populations. Kawada concludes in his review that cytoglobin, a member of
the mammalian globin family, is expressed in HSC and HSC-derived MFB but it is absent in MFB
derived from portal fibroblasts. Therefore, cytoglobin may be used in future studies requiring the
discrimination of both MFB subpopulations.
The review by Nwosu et al. shows that HSC transdifferentiation is accompanied by changes in
the main metabolic pathways, glycolysis, tricarboxylic acid cycle, as well as in glutamine, fatty acid,
and cholesterol metabolism. The authors demonstrate that the antioxidant defense system is also
affected and that autophagy, the process of degradation of cellular organelles to generate energy,
correlates with HSC activation. On the other hand, autophagy may protect from liver fibrosis
in certain circumstances. Gene expression in HSC is also modulated by epigenetic mechanisms.
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Lambrecht et al. discuss a possible role of miRNAs in liver
fibrosis. These short RNA molecules regulate gene expression
both in normal and pathological conditions. Hypoxia in the
liver cells that accompanies the development of fibrosis affects
a number of miRNAs. Several miRNAs have been implicated in
HSC activation.
Another review in the Research Topic highlights the role of
NADPH oxidases in mediating activation of MFB and hepatic
fibrogenesis. Chronic liver injury generates oxidative stress that
leads to the damage of lipids, proteins, and DNA and necrosis
and/or apoptosis of hepatocytes. Reactive oxygen species (ROS)
stimulate the production of profibrogenic mediators by Kupffer
cells and circulating inflammatory cells and activate HSC.
NADPH oxidases are the source of ROS and thus play a role in
HSC activation (Liang et al.).
Görtzen et al. have found that the activity of the GTPase RhoA
increases in cirrhotic liver and in activated HSC which leads to
decreased activity of the transmembrane protein c-SRC. As a
consequence, HSCmotility andmigration is decreased in favor of
contractility and ECM synthesis. The increasing tension of liver
tissue in the proces of fibrosis can be mimicked by culturing cells
on fibrinogen-coated polyacrylamide gels of variable stiffness.
Anti-fibrotic therapy may include protection of hepatocytes
from apoptosis as the dying cells release signals recruiting
immune cells to the sites of injury. According to the review by
Wang et al., the blocking of TGF-β action, the elimination of
activated HSC, and the inhibition of cholangiocyte proliferation
are possible ways of anti-fibrotic treatment. Various chemicals of
plant origin are tested as anti-fibrotic drugs. The hop constituent
xanthohumol has been shown to inhibit HSC activation and
hepatic carcinoma cell growth in vitro. However, as Weiskirchen
and his associates discuss in their review, relatively large doses of
xanthohumol need to be applied in animal experiments to inhibit
pro-fibrogenic gene expression.
In conclusion, the articles in this Research Topic deal with
the current topics of myofibroblast research—the origin of MFB
in the fibrotic septa of cirrhotic liver, the regulation of the cell
transdifferentiation and possible ways of fibrosis treatment. The
editors hope that the Research Topic will help researchers to solve
these problems.
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